Main image
28th September
written by Tellus

These agreements benefit regulators by reducing double inspections in any other area, allowing for a greater focus on higher-risk sites, and expanding inspection coverage of the global supply chain. In the coming months, the EU and the UK are expected to conclude an agreement that ensures the widest possible harmonisation and cooperation on medicines for human use. Given the precedents of previous agreements, a free trade agreement should also contain ambitious provisions on data exchange, intellectual property (IP) protection, tariff facilitation and rules of origin (RoO). The EU and the UK should set up a working group on medicines and medical devices, in line with the EU-South Korea Free Trade Agreement. *Restrictions: Capacity rules apply to routine surveillance inspections. . . .

Comments are closed.